术前乳腺 MRI 对导管原位癌长期生存的影响
本研究为回顾性队列研究,纳入 1003 例导管原位癌(DCIS)女性,其中 624 例(62.2%)接受术前乳腺 MRI。采用基于 25 个协变量的倾向评分加权法平衡组间差异,中位随访 9.5 年。结果显示术前 MRI 与无 MRI 组的 15 年复发率和总死亡率均无显著差异,术前 MRI 不是无复发生存或总生存的独立影响因素。
要点
- DCIS 患者常规术前乳腺 MRI 未改善长期复发或生存结局。
- 15 年复发率:MRI 组 27%,无 MRI 组 23%(p=0.77)。
- 术前 MRI 不应作为 DCIS 患者常规推荐,需前瞻性研究筛选获益亚组。
核心结论
- 术前乳腺 MRI 与 DCIS 女性无复发生存或总生存的改善无显著关联。
- 在倾向评分加权队列中,术前 MRI 与复发风险(HR 0.88,95%CI 0.60–1.30)和总死亡风险(HR 1.21,95%CI 0.55–2.66)均无统计学关联。
研究设计与样本
- 回顾性队列研究,纳入 2007 年 1 月至 2016 年 12 月诊断为导管原位癌的女性共 1003 例,平均年龄 48.6±9.4 岁。
- 624 例(62.2%)接受术前乳腺 MRI,采用基于 25 个临床病理协变量的倾向评分加权生成重叠加权队列以平衡组间差异。
- 中位随访 9.5 年,观察结局为无复发生存和总生存,采用 Kaplan-Meier 估计、log-rank 检验和 Cox 比例风险模型分析。
诊断标准与关键数值
- 15 年复发率:术前 MRI 组 27%,无 MRI 组 23%,差异无统计学意义(p=0.77)。
- 重叠加权队列中术前 MRI 与复发关联的 HR 为 0.88(95%CI 0.60–1.30,p=0.53),与总死亡关联的 HR 为 1.21(95%CI 0.55–2.66,p=0.64)。
- 多因素分析中术前 MRI 不是无复发生存的独立因素(HR 0.99,95%CI 0.71–1.39,p=0.95),也不是总生存的独立因素(HR 1.11,95%CI 0.52–2.37,p=0.78)。
- 中位随访期内 122 例(12%)出现复发,其中 75 例(61%)为浸润性复发。
临床应用与阅片要点
- DCIS 患者术前常规乳腺 MRI 未显示长期生存获益,报告中应避免暗示 MRI 可改善预后。
- 临床决策中术前 MRI 应审慎使用,不应作为 DCIS 的常规术前评估手段。
- 需要前瞻性多中心研究进一步明确可能从术前 MRI 中获得生存获益的 DCIS 亚组。
局限性
- 回顾性单中心研究设计存在选择偏倚和混杂偏倚可能,尽管采用倾向评分加权仍不能完全排除未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the impact of preoperative MRI on long-term survival outcomes in women with ductal carcinoma in situ (DCIS).
MATERIALS AND METHODS: This retrospective study included women diagnosed with DCIS between January 2007 and December 2016. Propensity scores based on 25 demographic and clinicopathologic covariates were used to generate an overlap-weighted cohort, balancing patient groups according to MRI use. Recurrence-free survival (RFS) and overall survival (OS) were compared using Kaplan-Meier estimates with log-rank test and Cox proportional hazards models.
RESULTS: Among 1003 eligible women (mean age, 48.6 years ± 9.4 [SD]), 624 (62.2%) underwent MRI. During a median follow-up of 9.5 years, 122 (12%) experienced recurrence, including 75 (61%) invasive events. The 15-year recurrence rates did not differ between the MRI and no-MRI groups (27% vs 23%; p = 0.77). Preoperative MRI was not associated with recurrence in the overlap-weighted cohort (hazard ratio (HR), 0.88 [95% CI: 0.60, 1.30]; p = 0.53). The 15-year overall mortality rate was 7% in both groups (p = 0.93), and preoperative MRI was not associated with overall mortality in the overlap-weighted cohort (HR, 1.21 [95% CI: 0.55, 2.66]; p = 0.64). Preoperative MRI was not an independent factor for RFS (HR, 0.99 [95% CI: 0.71, 1.39]; p = 0.95) or OS (HR, 1.11 [95% CI: 0.52, 2.37]; p = 0.78).
CONCLUSION: Preoperative breast MRI was not associated with improved RFS or OS among women with DCIS.
KEY POINTS: Question The impact of preoperative MRI on long-term outcomes in women with ductal carcinoma in situ (DCIS) remains uncertain. Findings In this retrospective propensity score-weighted analysis, preoperative breast MRI was not associated with improved recurrence-free survival or overall survival in women with DCIS. Clinical relevance Routine preoperative MRI may not improve long-term outcomes in DCIS. Prospective multicenter studies are warranted to identify subgroups that may derive meaningful survival benefits.
引用
- Kim, Choi, Yoon, et al. Preoperative breast MRI and long-term survival in ductal carcinoma in situ: a propensity score-weighted analysis. Eur Radiol. 2026. PMID: 42409986. doi:10.1007/s00330-026-12720-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。